ClinicalTrials.gg
Status unknownNCT03476564Updated Mar 26, 2018

Effects of Pentoxifylline and Vitamin E on Pregnancy Rate in Infertile Women Treated by ICSI:

An Early Phase 1 interventional study of pentoxifylline and Vit E in Infertility, Female, sponsored by Benha University. Status unknown at 1 site in Egypt. Open to female participants aged 20 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-26.

Sponsored by Benha University · Early Phase 1, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 60 studies in Infertility, Female with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Infertility, Female · Egypt.

Planned enrollment
24th of 46
140 · median 141
Started
2018
with 5 others
Phase 1
2 of 60
none open now
Registered
15th of 60
by date
Lead sponsor
2 of 60
Benha University

Among the 60 studies in Infertility, Female with a site in Egypt, this one is the 24th largest by planned enrollment of the 46 interventional ones that give a count, is one of 6 that started in 2018, is one of 2 in phase 1, and was the 15th registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 134 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

6 of the 60 studies in Infertility, Female with a site in Egypt are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 89 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 78 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 20 Years to 39 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Infertility, Female with a site in Egypt, or all of them as a file.
02

Study summary

Our findings will provide preliminary clinical evidence to suggest the new experimental treatment approaches, toward female factor infertility treatment with pentoxyfylline.

Read the detailed description

This randomized clinical trial will be conducted on 140 infertile patients. The study is approved by the Ethical Committee of Benha obstetrics and Gynecology Department and will be initiated after achieving written consents of the participants. The study will include infertile patients under 39 years of age without a previous history of ICSI cycle. Exclusion criteria will be hypothalamic amenorrhea, drug reactions or complications, endometriosis and fibroids. Patients will be randomly divided into two equal groups. Computer generated random number table will be used for randomization. Group assignments will be placed in sealed opaque sequentially numbered envelopes. For each participant a questionnaire will be filled by the researchers. The questionnaire contained questions about age, duration of infertility, the type and cause of infertility. Data will be collected from questionnaires, clinical, laboratory notes and ultrasound reports. Endometrial thickness will be measured on the day of the HCG prescription in both groups by one of the two attending physicians. Chemical pregnancy will be detected by serum beta-hCG analysis 14 days after embryo transfer and transvaginal ultrasound scan will be scheduled 2 weeks later to confirm the diagnosis of clinical pregnancy. The intervention group will receive pentoxifylline (Trental S.R.) 400 mg/BD plus vit E (PHARCO) 400 mg/BD 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled. The comparison group will not receive the above drugs. The main outcome measure will be clinical pregnancy rate.

Sample size calculation Sample size was calculated using PASS® version 11 program, setting the type-1 error (α) at 0.05 and the power (1-β) at 0.8. Results from a previous study (Ashraf alesyan, 2009) showed that the incidence of pregnancy rate among ttt group was 57.1% while for control group it was 39.2%, with an effect size of 12%. Calculation according to these values produced a minimal sample size of 131 cases in each group.

Results

Results will be statistically analyzed.

03

Conditions studied

  • Infertility, Female

Browse trials for

Keywords

  • assisted reproductive techniques
04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infertile female patients under 39 years

Exclusion criteria

Exclusion Criteria:

  • hypothalamic amenorrhea
  • drug reactions or complications
  • endometrioses
  • fibroids
05

Study design

Phase
Early Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    intervention group

    intervention group will receive pentoxifylline (Trental S.R.) 400 mg/BD plus vit E (PHARCO) 400 mg/BD 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled.

    Drug: pentoxifylline · Drug: Vit E

  • No intervention
    comparison group

    . The comparison group will not receive the above drugs. The main outcome measure will be clinical pregnancy rate.

Interventions

  • will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled

    Also known as: Trental S.R. 400 mg/BD

  • DrugVit E

    will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled

    Also known as: Vit E PHARCO 400 mg/BD

06

What researchers measure

Primary outcomes

  1. clinical pregnancy rate.

    serum beta-hCG analysis 14 days after embryo transfer

    Time frame: two weeks after embryo transfer

  2. clinical pregnancy rate

    transvaginal ultrasound scan will be scheduled 2 weeks after embryo transfer to confirm the diagnosis of clinical pregnancy

    Time frame: two weeks after embryo transfer

07

Study locations

1 site
  • El Galaa Teaching hosptial
    Cairo, Ghamra, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2018; primary completion for Sep 2018, 4 months later.

Of 15 phase 1 interventional studies under Infertility, Female, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2018
First posted
Mar 26, 2018
StartEst.
May 1, 2018
Primary completionEst.
Sep 1, 2018
CompletionEst.
Sep 1, 2018
Last update
Mar 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03476564
Lead sponsor
Benha University
Collaborators
El Galaa Teaching Hospital
Responsible party
Ahmed Amr Fayez (doctor, Benha University) — Principal investigator
First posted
Mar 26, 2018
Start date
May 1, 2018 (estimated)
Primary completion
Sep 1, 2018 (estimated)
Completion
Sep 1, 2018 (estimated)
Last update
Mar 26, 2018

Study contacts

ahmed amr fayez, M.B.B.CH
Contact
ahmed_fayez275@yahoo.com
(002)01066653186

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pentoxifylline

Start the discussion